Patient Safety Data Driving the Posture The FDAs enforcement posture is anchored in accumulated adverse event data: 455+ adverse event reports linked to compounded semaglutide as of early 2025 (current counts higher) 320+ adverse event reports linked to compounded tirzepatide as of early 2025 (current counts higher) Many reports involve dosing errors from patients self-administering incorrect amounts from multidose vials Several reports document hospitalization following severe nausea, dehydration, or pancreatitis Concerns about counterfeit products entering supply chains through online channels Cold-chain integrity issues with compounded shipments arriving warm or with inadequate temperature controls Salt-form substitution risks products containing semaglutide acetate or sodium rather than semaglutide base used in FDA-approved products These data points feature prominently in FDA communications and the Federal Register notice rationale

Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, et al
Understanding Semaglutide Dosages for Weight Loss The effectiveness of semaglutide largely depends on the correct dosage
Banerjee I, Mishra D, Das T, Maiti TK
It will reduce fat under your chin only, and help you get more defined jawline
Science 364 , 952955 (2019)